A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott,Yung-Jue Bang,Sarina Anne Piha-Paul,Albiruni Ryan Abdul Razak,Jaafar Bennouna,Jean-Charles Soria,Hope S. Rugo,Roger B. Cohen,Bert H. O'Neil,Janice M. Mehnert,Juanita Lopez,Toshihiko Doi,Emilie M.J. van Brummelen,Razvan Cristescu,Ping Yang,Kenneth Emancipator,Karen Stein,Mark Ayers,Andrew K. Joe,Jared Lunceford +19 more
TL;DR: Response patterns indicate that patients with tumors that had high levels of both TMB and inflammatory markers (GEP or PD-L1) represent a population with the highest likelihood of response to pembrolizumab in multiple tumor types.
Journal ArticleDOI
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers,Elizabeth R. Plimack,Jeffrey R. Infante,Brian I. Rini,David F. McDermott,Lionel D. Lewis,Martin H. Voss,Padmanee Sharma,Sumanta K. Pal,Albiruni Ryan Abdul Razak,Christian Kollmannsberger,Daniel Y.C. Heng,Jennifer L. Spratlin,M. Brent McHenry,Asim Amin +14 more
TL;DR: Nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising OS in patients with mRCC.
Journal ArticleDOI
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
Ruth Plummer,Gerhardt Attard,Simon Pacey,L. Li,Albiruni Ryan Abdul Razak,Rebecca Perrett,Mary Barrett,Ian Judson,Stan B. Kaye,N. L. Fox,Wendy Halpern,A. Corey,Hilary Calvert,Johann S. de Bono +13 more
TL;DR: Lexatumumab was safe and well tolerated at doses up to and including 10 mg/kg every 21 days and was associated with sustained stable disease in several patients, and consistent with a two-compartment model with first-order elimination from the central compartment.
Journal ArticleDOI
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman,Scott V. Bratman,S. Y. Cindy Yang,S. Y. Cindy Yang,Marco A. J. Iafolla,Marco A. J. Iafolla,Zhihui Liu,Zhihui Liu,Aaron R. Hansen,Aaron R. Hansen,Philippe L. Bedard,Philippe L. Bedard,Stephanie Lheureux,Stephanie Lheureux,Anna Spreafico,Anna Spreafico,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak,Svetlana Shchegrova,Maggie C. Louie,Paul Billings,Bernhard Zimmermann,Himanshu Sethi,Alexey Aleshin,Dax Torti,Kayla Marsh,Jenna Eagles,Iulia Cirlan,Youstina Hanna,Derek L. Clouthier,Scott C. Lien,Scott C. Lien,Pamela S. Ohashi,Pamela S. Ohashi,Wei Xu,Wei Xu,Lillian L. Siu,Lillian L. Siu,Trevor J. Pugh,Trevor J. Pugh +39 more
TL;DR: The potential for broad clinical utility of ctDNA-based surveillance in patients treated with ICB is demonstrated, and 12 patients with ct DNA clearance during treatment were alive with median 25 months follow up.
Journal ArticleDOI
Nasopharyngeal carcinoma: the next challenges.
Albiruni Ryan Abdul Razak,Lillian L. Siu,Fei-Fei Liu,Emma Ito,Brian O'Sullivan,Kelvin K. W. Chan +5 more
TL;DR: The specific challenges in pushing the boundaries of NPC treatments further are discussed, with an emphasis on prognostic/predictive markers, molecularly targeted therapies, immunotherapies and the areas of interest with regard to long-term toxicities arising from therapeutic interventions.